News | October 12, 2012

Neurosurgeon Mark P. Carol Honored by ASTRO For Contributions to IMRT, IGRT

ASTRO Mark P Carol Radiation Theraphy

October 12, 2012 – The American Society for Radiation Oncology (ASTRO) has named Mark P. Carol, M.D., a distinguished leader in the fields of intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT), as its 2012 Honorary Member, which is the highest honor the society bestows upon distinguished cancer researchers and leaders in disciplines other than radiation oncology, radiation physics or radiobiology. Carol will be recognized with this honor during the Awards Ceremony on Tuesday, Oct. 30, 2012, at 10:45 a.m., at ASTRO’s 54th Annual Meeting, Oct. 28 to 31, 2012, at the Boston Convention and Exhibition Center.

With more than 30 years of experience in the medical device and health care services arenas, Carol is often considered the father of IMRT. Since 1992, he has developed and created many novel and crucial devices and techniques that have influenced and shaped modern radiation oncology, such as computed tomography (CT)/ magnetic resonance imaging (MRI) image fusion with ultrasound treatment room-based localization, intensity modulated treatment delivery, DVH-based prescriptions, simulated annealing optimization and image-guided therapy. Most recently, Carol has been developing an innovative way to deliver radiation therapy that uses a multiplexed photon beam to treat patients in sitting and standing positions, thereby reducing overall costs while at the same time allowing advanced multimodality imaging to be introduced seamlessly into the treatment room.

“Throughout the years, Carol, who trained as a neurosurgeon, has been a pioneer and innovator in the field of radiation oncology,” said Michael L. Steinberg, M.D., FASTRO, ASTRO president. “His groundbreaking approach to the development of IMRT and IGRT has provided tremendous benefits for radiation oncology patients. He is most deserving of this year’s honor.”

Serving as a founder, CEO and president for numerous corporations, Carol has constantly proven himself to be a successful innovator within the field of radiation oncology. He was awarded the Pittsburgh Business Times’ Health Care Hero Competition Award and the Ira Sohn Research Conference Prize in Pediatric Oncology from the Gotham Prize for Cancer Research. In 2004, Carol also garnered honorary membership in the American Association of Physicists in Medicine (AAPM).

Carol is a graduate of Amherst College in Amherst, Mass., as an independent scholar, and he graduated with distinction in research from the University of Rochester’s School of Medicine & Dentistry in Rochester, N.Y. At the University of Rochester, Carol worked on developing an artificial heart, for which he now holds a patent. From 1978-1984, he served as a neurosurgical resident and a fellow in neurotraumatology at the University of Maryland in College Park, M.D., and he later went on to practice at the Mary Imogene Bassett Hospital in Cooperstown, N.Y. He has also taught as an assistant professor of neurosurgery at Columbia University in New York, the University of South Florida in Tampa, Fla., and the Medical College of Ohio in Toledo, Ohio. Since 2009, Carol has been an adjunct assistant professor of radiation oncology at Brown University in Providence, R.I. He is currently the chief development officer at U.S. HIFU, an innovator in the use of high intensity focused ultrasound for thermal ablation, based in Charlotte, N.C.

For more information: www.astro.org

Related Content

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
IBA Announces First Use of Gating With Active Scanning Proton Therapy in Italy
News | Proton Therapy | October 17, 2017
October 17, 2017 — The Trento Azienda Provinciale per i Servizi Sanitari (APSS) and IBA announced the successful comp
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation Therapy, MRI guided RT.
Sponsored Content | Webinar | Radiation Therapy | October 13, 2017
The webinar "Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation" will be presented by Par
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
Overlay Init